XBiotech Inc (XBIT) NPV

Sell:$3.10Buy:$3.11$0.22 (6.55%)

NASDAQ:1.36%
Market closed | Prices delayed by at least 15 minutes
Sell:$3.10
Buy:$3.11
Change:$0.22 (6.55%)
Market closed | Prices delayed by at least 15 minutes
Sell:$3.10
Buy:$3.11
Change:$0.22 (6.55%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Key people

John Simard
Chairman of the Board, President, Chief Executive Officer, Founder
Angela Hu
Director of Finance
Sushma Shivaswamy
Chief Scientific Officer
Jan-Paul Waldin
Lead Independent Director
Tak Mak
Director
Peter Libby
Independent Director
Donald H. Macadam
Independent Director
W. Thorpe Jerome McKenzie
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CA98400H1029
  • Market cap
    $104.25m
  • Employees
    92
  • Shares in issue
    30.48m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.